Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Masashi Aonuma"'
Autor:
Masaki Miyazaki, Yoshinobu Shiose, Masashi Aonuma, Yoshida Keisuke, Haruko Kawato, Mayumi Kitagawa, Hironari Shimizu, Tsunehiko Soga, Hiroyuki Naito, Setsuko Fukutake, Takahiko Seki, Tooru Okayama, Masaya Miyazaki, Yuuichi Sugimoto
Publikováno v:
Bioorganic & Medicinal Chemistry. 21:4319-4331
We have discovered and reported potent p53-MDM2 interaction inhibitors possessing dihydroimidazothiazole scaffold. Our lead showed strong activity in vitro, but did not exhibit antitumor efficacy in vivo for the low metabolic stability. In order to o
Autor:
Masashi Aonuma, Tsunehiko Soga, Masaki Miyazaki, Hiroyuki Naito, Yuuichi Sugimoto, Haruko Kawato, Setsuko Fukutake, Hironari Shimizu, Masaya Miyazaki, Takahiko Seki, Tooru Okayama, Mayumi Kitagawa
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 23:728-732
With the aim of discovering potent inhibitors of the p53-MDM2 interaction and thus obtaining a potent anticancer drug, we have pursued synthesis and optimization of dihydroimidazothiazole derivatives, which have been discovered via scaffold hopping b
Autor:
Hiroyuki Naito, Masaki Miyazaki, Takahiko Seki, Masashi Aonuma, Tsunehiko Soga, Masahiro Ikeda, Masaya Miyazaki, Mayumi Kitagawa, Haruko Kawato, Setsuko Fukutake
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 22:6338-6342
Starting with Nutlins as an initial lead, we designed and generated bicyclic scaffolds aiming to place cis-bischlorophenyl moiety at the equivalent location where the hydrophobic interaction with MDM2 could be expected. As a result, we discovered nov
Autor:
Hiroyuki Naito, Yoshida Keisuke, Yuuichi Sugimoto, Tsunehiko Soga, Haruko Kawato, Masaki Miyazaki, Takahiko Seki, Setsuko Fukutake, Tooru Okayama, Kouichi Uoto, Masaya Miyazaki, Masashi Aonuma, Mayumi Kitagawa
Publikováno v:
Bioorganicmedicinal chemistry. 23(10)
We have published p53-MDM2 interaction inhibitors possessing a novel dihydroimidazothiazole scaffold. Although our lead compound 1 showed strong antitumor activity with single oral administration on a xenograft model using MV4-11 cells harboring wild
Autor:
Masashi Aonuma, Hiromi Sakamoto, Kenji Murakami, Masaaki Terada, Kenji Hirotani, Tadashi Horiuchi, Noriko G. Tanaka
Publikováno v:
Angiogenesis (incorporating Angiogenesis Research). 2:143-152
The hst-1 gene product, one of the fibroblast growth factor family proteins, has transforming and angiogenic activities. The BALB/c 3T3 cell line was transfected with an expression vector harboring human hst-1 cDNA and the malignant properties of two
Autor:
Kenji Murakami, Chiharu Hattori, Masashi Aonuma, Yutaka Nakayama, Kenji Hirotani, Noriko G. Tanaka, Masabumi Shibuya, Michio Iwahana
Publikováno v:
Angiogenesis. 2:57-66
The aim of this study was to determine the role of tumor-derived angiogenic factors in solid tumor formation. We compared the angiogenic potential of tumorigenic and non-tumorigenic human tumor cell lines. All tumorigenic cell lines induced angiogene
Publikováno v:
Biopharmaceutics & Drug Disposition. 16:653-667
We investigated the biodistribution and antitumour activity of doxorubicin (ADM) encapsulated in liposomes (L-ADM) after two administrations in tumour bearing mice. The effect of the first administration on phagocytic activity was also examined. The
Autor:
Masamichi Sugimori, Satoru Ohsuki, Yasuhide Hirota, Eiji Kumazawa, Masashi Aonuma, Kouichi Uoto, Hirofumi Terasawa, Akio Ejima, Ikuo Mitsui, Keiki Sato
Publikováno v:
Japanese Journal of Cancer Research : Gann
CPT‐11, a semisynthetic derivative of camptothecin, exhibited strong antitumor activity against lymphoma, lung cancer, colorectal cancer, gastric cancer, ovarian cancer, and cervical cancer. CPT‐11 is a pro‐drug that is converted to an active m
Publikováno v:
Drug Metabolism and Pharmacokinetics. 6:899-907
It is known that SN-38, a main metabolite of the novel camptothecin derivative CPT-11, shows a more potent anti-proliferative effect than CPT-11, in vitro. Therefore, it is presumed that SN-38 greatly influences the antitumor effect of CPT-11. In thi
Publikováno v:
Oncogene. 27(40)
Nutlin-3 is a selective inhibitor of the p53-Mdm2 interaction, and inhibits growth in most tumor cells with wild-type p53. However, it only induces apoptosis in subsets of tumor cells. We report that the apoptotic response induced by Nutlin-3 correla